A Double-Blind Placebo-Controlled Study of Lamotrigine Monotherapy in Outpatients With Bipolar I Depression
The DOI matches its Crossref record.
Abstract
BACKGROUND: More treatment options for bipolar depression are needed. Currently available antidepressants may increase the risk of mania and rapid cycling, and mood stabilizers appear to be less effective in treating depression than mania. Preliminary data suggest that lamotrigine, an established antiepileptic drug, may be effective for both the depression and mania associated with bipolar disorder. This is the first controlled multicenter study evaluating lamotrigine monotherapy in the treatment of bipolar I depression. METHODS: Outpatients with bipolar I disorder experiencing a major depressive episode (DSM-IV, N = 195) received lamotrigine (50 or 200 mg/day) or placebo as monotherapy for 7 weeks. Psychiatric evaluations, including the Hamilton Rating Scale for Depression (HAM-D), the Montgomery-Asberg Depression Rating Scale (MADRS), Mania Rating Scale, and the Clinical Global Impressions scale for Severity (CGI-S) and Improvement (CGI-I) were completed at each weekly visit. RESULTS: Lamotrigine 200 mg/day demonstrated significant antidepressant efficacy on the 17-item HAM-D, HAM-D Item 1, MADRS, CGI-S, and CGI-I compared with placebo. Improvements were seen as early as week 3. Lamotrigine 50 mg/day also demonstrated efficacy compared with placebo on several measures. The proportions of patients exhibiting a response on CGI-I were 51%, 41%, and 26% for lamotrigine 200 mg/day, lamotrigine 50 mg/day, and placebo groups, respectively. Adverse events and other safety results were similar across treatment groups, except for a higher rate of headache in the lamotrigine groups. CONCLUSION: Lamotrigine monotherapy is an effective and well-tolerated treatment for bipolar depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“while clinical experience and the results of many studies suggest that response to mood stabilizers and antipsychotics is similar in BDII and BDI, there are enough exceptions to suggest this should not be taken for granted.248, 405, 431”
Citations
Cites
Still being checked.
Cited by
Items 101–200 of 1,000
Andrade, C. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15f10377 · Cited by 133
Bahji, A., Ermacora, D., Stephenson, C., Hawken, E. R., & Vazquez, G. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.030 · Cited by 139
Review of the use of Topiramate for treatment of psychiatric disorders
Arnone, D. (2005) · Annals of General Psychiatry · doi:10.1186/1744-859x-4-5 · Cited by 134
Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry
Fountoulakis, K. Ν., Kasper, S. F., Andreassen, O. A., Blier, P., Okasha, A., Severus, E., Versiani, M., Tandon, R., Möller, H., & Vieta, E. (2012) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0323-x · Cited by 149
Cognitive and behavioral effects of antiepileptic drugs
Drane, D. L., & Meador, K. J. (2002) · Epilepsy & Behavior · doi:10.1016/s1525-5069(02)00502-9 · Cited by 134
Effects of Antiepileptic Drugs on Mood and Behavior
Schmitz, B. (2006) · Epilepsia · doi:10.1111/j.1528-1167.2006.00684.x · Cited by 133
Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
Schaffer, A., Zuker, P., & LEVITT, A. J. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.05.023 · Cited by 133
Selle, V., Schalkwijk, S., Vázquez, G., & Baldessarini, R. (2014) · Pharmacopsychiatry · doi:10.1055/s-0033-1363258 · Cited by 128
Clinical practice recommendations for bipolar disorder
Malhi, G. S., Adams, D., Lampe, L., Paton, M., O’Connor, N., Newton, L. A., Walter, G., Taylor, A., Porter, R., Mulder, R. T., et al. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01383.x · Cited by 129
Newer antiepileptic drugs: Possible uses in the treatment of neuropathic pain and migraine
Pappagallo, M. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80314-4 · Cited by 131
Taylor, D. M., Cornelius, V., Smith, L., & Young, A. H. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12343 · Cited by 122
Farber, N. B., Jiang, X.-P., Heinkel, C., & Nemmers, B. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001087 · Cited by 128
Pinto, O., & Akiskal, H. S. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00007-5 · Cited by 139
Treatment Options for Bipolar Depression: A Systematic Review of Randomized, Controlled Trials
Vieta, E., Locklear, J., Günther, O., Ekman, M., Miltenburger, C., Chatterton, M. L., Åström, M., & Paulsson, B. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181f15849 · Cited by 119
Report of the Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder 2000
Suppes, T., Dennehy, E. B., Swann, A. C., Bowden, C. L., Calabrese, J. R., Hirschfeld, R. M. A., Keck, P. E., Sachs, G. S., Crismon, M. L., Toprac, M. G., et al. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0404 · Cited by 119
Self-citationFountoulakis, K. N., Yatham, L., Grunze, H., Vieta, E., Young, A., Blier, P., Kasper, S., & Moeller, H. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw100 · Cited by 116
Potential Mechanisms of Action of Lamotrigine in the Treatment of Bipolar Disorders
Ketter, T. A., Manji, H. K., & Post, R. M. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000088915.02635.e8 · Cited by 117
Lamotrigine Compared with Lithium in Mania: A Double-Blind Randomized Controlled Trial
Ichim, L., Berk, M., & Brook, S. (2000) · Annals of Clinical Psychiatry · doi:10.1023/a:1009066725103 · Cited by 114
The Stanley Foundation Bipolar Network: 1. Rationale and methods
Post, R. M., Denicoff, K. D., Leverich, G. S., Nolen, W. A., Kupka, R. W., Keck, P. E., McElroy, S. L., Rush, A. J., Suppes, T., Altshuler, L. L., et al. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.41.s169 · Cited by 113
Charney, D. S. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.3.262 · Cited by 113
Safety and Tolerability of Lamotrigine for Bipolar Disorder
Bowden, C. L., Asnis, G. M., Ginsberg, L. D., Bentley, B., Leadbetter, R. A., & White, R. (2004) · Drug Safety · doi:10.2165/00002018-200427030-00002 · Cited by 114
Self-citationPhenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine
Passmore, M. J., Garnham, J., Duffy, A., MacDougall, M., Munro, A., Slaney, C., Teehan, A., & Alda, M. (2003) · Bipolar Disorders · doi:10.1034/j.1399-5618.2003.00026.x · Cited by 109
Keitner, G. I., Garlow, S. J., Ryan, C. E., Ninan, P. T., Solomon, D. A., Nemeroff, C. B., & Keller, M. B. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.05.003 · Cited by 108
“The HAMD is a 17-item clinician rated scale that is weighed towards somatic complaints (Calabrese et al., 1999).”
BackgroundMethodTreatment of bipolar disorder in older adults
Sajatovic, M. (2002) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.719 · Cited by 107
Kremer, I., Vass, Á., Gorelik, I., Bar, G., Blanaru, M., Javitt, D. C., & Heresco‐Levy, U. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.06.029 · Cited by 107
Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression
Schatzberg, A. F., & Kraemer, H. C. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00846-5 · Cited by 106
Inositol as an add‐on treatment for bipolar depression
Chengappa, K. R., Levine, J., Gershon, S., Mallinger, A. G., Hardan, A., Vagnucci, A., Pollock, B., Luther, J., Buttenfield, J., Verfaille, S., et al. (2000) · Bipolar Disorders · doi:10.1034/j.1399-5618.2000.020107.x · Cited by 102
Risperidone and Paroxetine Given Singly and in Combination for Bipolar Depression
Shelton, R. C., & Stahl, S. M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1218 · Cited by 100
Aldenkamp, A. P., Arends, J., Bootsma, H. P. R., Diepman, L., Hulsman, J., Lambrechts, D., Leenen, L., Majoie, M., Schellekens, A., & De Vocht, J. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.29201.x · Cited by 99
Obrocea, G. V., Dunn, R. M., Frye, M. A., Ketter, T. A., Luckenbaugh, D. A., Leverich, G. S., Speer, A. M., Osuch, E. A., Jajodia, K., & Post, R. M. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01206-9 · Cited by 105
Behavioural Effects of the New Anticonvulsants
Besag, F. (2001) · Drug Safety · doi:10.2165/00002018-200124070-00004 · Cited by 103
Antisuicide Properties of Psychotropic Drugs: A Critical Review
Ernst, C. L., & Goldberg, J. F. (2004) · Harvard Review of Psychiatry · doi:10.1080/10673220490425924 · Cited by 32
Disruption of prepulse inhibition in mice lacking mGluR1
Brody, S. A., Conquet, F., & Geyer, M. A. (2003) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2003.03073.x · Cited by 94
Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications.
Keck, P. E., & McElroy, S. L. (2002) · PubMed · Cited by 95
Maintenance Treatment Outcomes in Older Patients with Bipolar I Disorder
Sajatovic, M., Gyulai, L., Calabrese, J. R., Thompson, T. R., Wilson, B. G., White, R., & Evoniuk, G. (2005) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200504000-00006 · Cited by 93
Self-citationKetamine and other potential glutamate antidepressants
Dutta, A., McKie, S., & Deakin, J. F. W. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.10.028 · Cited by 98
Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania
Arban, R., Maraia, G., Brackenborough, K. T., Winyard, L. A., Wilson, A. W., Gerrard, P. A., & Large, C. H. (2004) · Behavioural Brain Research · doi:10.1016/j.bbr.2004.08.015 · Cited by 93
Nierenberg, A. A., Friedman, E. S., Bowden, C. L., Sylvia, L. G., Thase, M. E., Ketter, T. A., Ostacher, M. J., Leon, A. C., Reilly-Harrington, N. A., Iosifescu, D. V., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12060751 · Cited by 97
Self-citationPolytherapy in Bipolar Disorder
Lin, D., Mok, H., & Yatham, L. N. (2006) · CNS Drugs · doi:10.2165/00023210-200620010-00003 · Cited by 91
Li, X., Tenebäck, C. C., Nahas, Z. H., Kozel, F. A., Large, C. H., Cohn, J., Bohning, D. E., & George, M. S. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300452 · Cited by 100
Li, X., Ketter, T. A., & Frye, M. A. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00361-x · Cited by 108
Effects of lamotrigine and levetiracetam on seizure development in a rat amygdala kindling model
Stratton, S. C., Large, C. H., Cox, B., Davies, G., & Hagan, R. M. (2003) · Epilepsy Research · doi:10.1016/s0920-1211(02)00254-1 · Cited by 89
Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder
Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Bipolar Disorder (2004) · Australian and New Zealand Journal of Psychiatry · doi:10.1111/j.1440-1614.2004.01356.x · Cited by 90
Bipolar depression: issues in diagnosis and treatment
Thase, M. E. (2005) · Harvard Review of Psychiatry · doi:10.1080/10673220500326425 · Cited by 89
Psychopharmacology of topiramate: from epilepsy to bipolar disorder
Cavanna, A. E., Monaco, F., Mula, M., Robertson, M. M., & Critchley, H. (2006) · Neuropsychiatric Disease and Treatment · doi:10.2147/nedt.2006.2.4.475 · Cited by 95
Biederman, J., Joshi, G., Mick, E. O., Doyle, R., Georgiopoulos, A. M., Hammerness, P. G., Kotarski, M., Williams, C., & Wozniak, J. R. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00121.x · Cited by 89
Treatment of bipolar depression: An update
Fountoulakis, K. Ν., Grunze, H., Panagiotidis, P., & Kaprinis, G. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.10.016 · Cited by 93
Duailibi, M. S., Cordeiro, Q., Brietzke, E., Ribeiro, M., LaRowe, S., Berk, M., & Trevizol, A. P. (2017) · The American Journal on Addictions · doi:10.1111/ajad.12620 · Cited by 82
Developing novel treatments for mood disorders: accelerating discovery
Tamminga, C. A., Nemeroff, C. B., Blakely, R., Brady, L. S., Carter, C. S., Davis, K. L., Dingledine, R. J., Gorman, J. M., Grigoriadis, D. E., Henderson, D. C., et al. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01470-1 · Cited by 94
Edwards, K. R., Sackellares, J. C., Vuong, A., Hammer, A. E., & Barrett, P. S. (2001) · Epilepsy & Behavior · doi:10.1006/ebeh.2000.0143 · Cited by 85
The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder
Chengappa, K. R., Gershon, S., & Levine, J. (2001) · Bipolar Disorders · doi:10.1034/j.1399-5618.2001.030501.x · Cited by 85
The Recognition and Management of Mood Disorders as a Comorbidity of Epilepsy
Barry, J. J. (2003) · Epilepsia · doi:10.1046/j.1528-1157.44.s4.4.x · Cited by 83
Borderline personality disorder in patients with bipolar disorder and response to lamotrigine
Preston, G. A., Marchant, B. K., Reimherr, F. W., Strong, R. E., & Hedges, D. W. (2004) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00358-0 · Cited by 82
A meta-analysis of the use of typical antipsychotic agents in bipolar disorder
Tohen, M. F., Zhang, F., Taylor, C. C., Burns, P., Zarate, C. A., Sanger, T. M., & Tollefson, G. D. (2001) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00162-2 · Cited by 82
Behavioural effects of the newer antiepileptic drugs: an update
Besag, F. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.1.1 · Cited by 81
Yatham, L. N., Vieta, E., Goodwin, G. M., Bourin, M., de Bodinat, C., Laredo, J., & Calabrese, J. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.147587 · Cited by 79
Self-citationLicht, R. W., Vestergaard, P., Kessing, L. V., Larsen, J. K., & Thomsen, P. H. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.108.s419.1.x · Cited by 81
Tiagabine in the treatment of acute affective episodes in bipolar disorder
Vasudev, A., Macritchie, K., Rao, S. N., Geddes, J. R., & Young, A. H. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004694.pub2 · Cited by 80
Elevated spectroscopic glutamate/γ-amino butyric acid in rats bred for learned helplessness
Sartorius, A., Mahlstedt, M. M., Vollmayr, B., Henn, F. A., & Ende, G. (2007) · NeuroReport · doi:10.1097/wnr.0b013e3282742153 · Cited by 73
Licht, R. W., Nielsen, J. N., Gram, L. F., Vestergaard, P., & Bendz, H. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2010.00836.x · Cited by 79
Antiepileptic Drugs in the Treatment of Anxiety Disorders: Role in Therapy
Ameringen, M. V., Mancini, C., Pipe, B., & Bennett, M. (2004) · Drugs · doi:10.2165/00003495-200464190-00004 · Cited by 84
Yoon, S. J., Lyoo, I. K., Haws, C. A., Kim, T. S., Cohen, B. M., & Renshaw, P. F. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.2 · Cited by 81
Current issues in bipolar disorder: A critical review
Oswald, P., Souery, D., Kasper, S. F., Lecrubier, Y., Montgomery, S., Wyckaert, S., Zohar, J., & Mendlewicz, J. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.03.006 · Cited by 87
Cognitive Dysfunction in Bipolar Disorder: Future Place of Pharmacotherapy
Burdick, K. E., Braga, R. J., Goldberg, J. F., & Malhotra, A. K. (2007) · CNS Drugs · doi:10.2165/00023210-200721120-00002 · Cited by 102
Cognitive and Behavioral Effects of Antiepileptic Drugs
Meador, K. J., Gilliam, F. G., Kanner, A. M., & Pellock, J. M. (2001) · Epilepsy & Behavior · doi:10.1006/ebeh.2001.0235 · Cited by 77
Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder
Fountoulakis, K. N., Vieta, E., Siamouli, M., Valenti, M., Magiria, S., Oral, T., Fresno, D., Giannakopoulos, P., & Kaprinis, G. S. (2007) · Annals of General Psychiatry · doi:10.1186/1744-859x-6-27 · Cited by 76
Treatment‐resistant bipolar depression: towards a new definition
Pacchiarotti, I., Mazzarini, L., Colom, F., Sanchez‐Moreno, J., Girardi, P., Kotzalidis, G. D., & Vieta, E. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01471.x · Cited by 74
Yatham, L. N., Kusumakar, V., Calabrese, J. R., Rao, R., Scarrow, G., & Kroeker, G. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0402 · Cited by 77
Self-citationMetabolism and Excretion of Mood Stabilizers and New Anticonvulsants
Ketter, T. A., Frye, M. A., Cora‐Locatelli, G., Kimbrell, T. A., & Post, R. M. (1999) · Cellular and Molecular Neurobiology · doi:10.1023/a:1006990925122 · Cited by 75
Lombardo, I., Sachs, G., Kolluri, S., Kremer, C., & Yang, R. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825ccde5 · Cited by 75
Self-citationAmsterdam, J. D., & Shults, J. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318166c4e6 · Cited by 71
Kaster, M. P., Raupp, I. M., Binfaré, R. W., Andreatini, R., & Rodrigues, A. L. S. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.03.003 · Cited by 75
Management of bipolar depression with lamotrigine: an antiepileptic mood stabilizer
Prabhavalkar, K. S., Poovanpallil, N. B., & Bhatt, L. K. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00242 · Cited by 70
Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression
Brown, E., Dunner, D. L., McElroy, S. L., Keck, P. E., Adams, D. H., Degenhardt, E., Tohen, M., & Houston, J. P. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009735 · Cited by 73
“However, patients were receiving 50 mg/d Lam starting at week 2; at 50 mg/d Lam has been shown to be effective compared with placebo in a 7-wk study of acute bipolar I depression (Calabrese et al. 1999).”
BackgroundResultInfluentialControlled trials in bipolar I depression: focus on switch rates and efficacy
Calabrese, J. R., RAPPORT, D. J., Kimmel, S. E., & Shelton, M. D. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)00023-1 · Cited by 75
Self-citationMaintenance Therapies in Bipolar Disorder: Focus on Randomized Controlled Trials
Muzina, D. J., & Calabrese, J. R. (2005) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2005.01649.x · Cited by 78
Self-citationAntiepileptic drug use in nursing home admissions
Garrard, J. M., Harms, S. L., Hardie, N. A., Eberly, L. E., Nitz, N., Bland, P. C., Gross, C. R., & Leppik, I. E. (2003) · Annals of Neurology · doi:10.1002/ana.10593 · Cited by 73
Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology
Quiroz, J. A., Singh, J. B., Gould, T. D., Denicoff, K. D., Zarate, C. A., & Manji, H. K. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001521 · Cited by 75
Classical and novel approaches to the preclinical testing of anxiolytics: A critical evaluation
Haller, J., Aliczki, M., & Gyimesi-Pelczer, K. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.09.001 · Cited by 74
The primacy of mania: A reconsideration of mood disorders
Koukopoulos, A., & Ghaemi, S. N. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2008.07.006 · Cited by 84
Nierenberg, A. A., Sylvia, L. G., Leon, A. C., Reilly-Harrington, N. A., Shesler, L. W., McElroy, S. L., Friedman, E. S., Thase, M. E., Shelton, R. C., Bowden, C. L., et al. (2013) · Clinical Trials · doi:10.1177/1740774513512184 · Cited by 73
Self-citationThe pharmacological management of depression
Kupfer, D. J. (2005) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2005.7.3/dkupfer · Cited by 69
Safety and tolerability of emerging pharmacological treatments for bipolar disorder
Dünner, D. L. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00235.x · Cited by 74
Investigating the mechanism(s) underlying switching between states in bipolar disorder
Young, J. W., & Dulcis, D. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.019 · Cited by 68
“Neither lamotrigine nor riluzole, which inhibit glutamate release, do not increase switching in depressed BD patients (Calabrese et al., 1999; McIntyre et al., 2013; Zarate Jr. et al., 2005).”
BackgroundEffect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice
Brody, S. A., Conquet, F., & Geyer, M. A. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1635-3 · Cited by 71
Haldane, M., Jogia, J., Cobb, A., Kozuch, E., Kumari, V., & Frangou, S. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.05.009 · Cited by 75
Anand, A., Gunn, A. D., Barkay, G., Karne, H. S., Nurnberger, J. I., Mathew, S. J., & Ghosh, S. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00971.x · Cited by 65
Neurobiology of bipolar disorder
Newberg, A. R., Catapano, L. A., Zarate, C. A., & Manji, H. K. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.1.93 · Cited by 75
Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice
Brody, S. A., Geyer, M. A., & Large, C. H. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1421-2 · Cited by 75
Medication Use in Children and Adolescents Treated in the Community for Bipolar Disorder
Bhangoo, R. K., Lowe, C. H., Myers, F. S., Treland, J. E., Curran, J., Towbin, K. E., & Leibenluft, E. (2003) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454603322724904 · Cited by 69
Managing the side effects associated with commonly used treatments for bipolar depression
Kemp, D. E. (2014) · Journal of Affective Disorders · doi:10.1016/s0165-0327(14)70007-2 · Cited by 62
Guideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders, 2012
Kanba, S., Kato, T., Terao, T., Yamada, K., & Committee for Treatment Guidelines of Mood Disorders, J. S. O. M. D. (2013) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12060 · Cited by 68
Solmi, M., Veronese, N., Zaninotto, L., van der Loos, M. L. M., Gao, K., Schaffer, A., Reis, C., Normann, C., Anghelescu, I.-G., & Correll, C. U. (2016) · CNS Spectrums · doi:10.1017/s1092852916000523 · Cited by 69
Szegedi, A., Durgam, S., Mackle, M., Yu, S. Y., Wu, X., Mathews, M., & Landbloom, R. P. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16040419 · Cited by 66
The Specificity of Platelet Glutamate Receptor Supersensitivity in Psychotic Disorders
Berk, M., Plein, H., & Belsham, B. (2000) · Life Sciences · doi:10.1016/s0024-3205(00)80002-8 · Cited by 75
Bipolar Depression in a Low-Income Primary Care Clinic
Olfson, M., Das, A. K., Gameroff, M. J., Pilowsky, D., Feder, A., Gross, R., Lantigua, R., Shea, S., & Weissman, M. M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.11.2146 · Cited by 66
Newer treatment studies for bipolar depression
Gao, K., & Calabrese, J. R. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00250.x · Cited by 67
Self-citationPublication Bias, with a Focus on Psychiatry: Causes and Solutions
Turner, E. H. (2013) · CNS Drugs · doi:10.1007/s40263-013-0067-9 · Cited by 70
Mood Stabilizers and Ion Regulation
El‐Mallakh, R. S., & Huff, M. O. (2001) · Harvard Review of Psychiatry · doi:10.1080/10673220127873 · Cited by 69
Metadata
- Authors
- Calabrese, J. R., Bowden, C. L., Sachs, G. S., Ascher, J. A., Monaghan, E., Rudd, G. D., & The Lamictal 602 Study Group
- Affiliations
- Case Western Reserve University (US)
- GlaxoSmithKline (United Kingdom) (GB)
- ORCID
- Calabrese, Joseph R.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 1999-02-15
- Volume
- 60
- Issue
- 2
- Pages
- 79-88
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2058120764
- Cited by
- 1,054
- References
- 0
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 15 · 2023: 8 · 2022: 8 · 2021: 7 · 2020: 162 · 2019: 10 · 2018: 13 · 2017: 13 · 2016: 13 · 2015: 18 · 2014: 23 · 2013: 24 · 2012: 34
- FWCI
- 47.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Keywords
- lamotrigine, bipolar I depression, bipolar disorder, antidepressant monotherapy, antiepileptic drugs, major depressive episode, treatment response, adverse events, headache, drug tolerability
- MeSH terms
- Lamotrigine, Adult, Aged, Ambulatory Care, Anticonvulsants, Bipolar Disorder, Depressive Disorder, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Patient Compliance, Placebos, Psychiatric Status Rating Scales, Severity of Illness Index, Triazines, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.